Sichuan Biokin Pharmaceutical Co.,Ltd.(688506),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

688506 Sichuan Biokin Pharmaceutical Co.,Ltd.

Closed 12-12 15:00:01

359.93

-2.13

-0.59%

High364.70	Low354.05	Vol1.00M
Open362.05	D1 Closing362.06	Amplitude2.94%
Mkt Cap148.65B	Tradable Cap37.07B	Total Shares413.00M
T/O362.00M	T/O Rate0.98%	Tradable Shares103.00M
P/B20.72	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"Sichuan Biokin Pharmaceutical Co.,Ltd.","latestPrice":359.93,"timestamp":1765522801000,"preClose":362.06,"halted":0,"volume":1004515,"delay":0,"changeRate":-0.0059,"floatShares":103000000,"shares":413000000,"eps":-2.0646,"marketStatus":"Closed","change":-2.13,"latestTime":"12-12 15:00:01","open":362.05,"high":364.7,"low":354.05,"amount":362000000,"amplitude":0.0294,"askPrice":359.93,"askSize":5,"bidPrice":359.9,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-2.0646,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":362.06,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":398.27,"lowLimit":325.85,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":20.72,"roa":"--","roe":"--","epsLYR":9.25,"committee":-0.395349,"marketValue":148606000000,"turnoverRate":0.0098,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2025-12-15.","afterMarket":{"amount":0,"volume":0,"close":359.93,"buyVolume":0,"sellVolume":0,"time":1765524839585,"indexStatus":"Closed 12-12 15:30:00","preClose":362.06},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"BIOKIN","latestPrice":0,"timestamp":1765526400000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":37034000000},"requestUrl":"/m/hq/s/688506/tweets","defaultTab":"tweets","newsList":[{"id":"2587991227","title":"Sichuan Biokin Pharma Says Co Remains Eligible for up to $250 Mln Near-Term Payments, up to $7.1 Bln Additional Payments Upon Achieving Specific Development, Regulatory, Commercial Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2587991227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587991227?lang=en_us&edition=fundamental","pubTime":"2025-11-30 17:16","pubTimestamp":1764494203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251130:nL4N3X602O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1074936037.SGD","LU1032466523.USD","LU0456855351.SGD","LU1093756168.USD","LU0321505439.SGD","LU1670711040.USD","LU1323610961.USD","LU0306807586.USD","LU0267386448.USD","BMY","BK4559","LU1868837136.USD","LU2360032135.SGD","LU0868494617.USD","LU0882574055.USD","IE00BFXG1179.USD","LU1430594728.SGD","LU1261432733.SGD","LU1093756325.SGD","LU0321505868.SGD","LU1868836757.USD","IE0009355771.USD","LU0225771236.USD","BK4585","BK4588","LU1291159041.SGD","BK4007","LU1670710661.SGD","LU1989771016.USD","688506","LU0096364046.USD","LU0061475181.USD","IE00BJT1NW94.SGD","LU1868836591.USD","LU0237698245.USD","LU0225284248.USD","IE00BFTCPJ56.SGD","LU1670710588.SGD","LU2242652126.USD","LU1670711123.USD","BK4581","BK4532","LU1585245621.USD","LU2133065610.SGD","IE00B2B36J28.USD","BK0239","IE00BSNM7G36.USD","LU1868837300.USD","IE00BJJMRZ35.SGD","LU0306806265.USD"],"gpt_icon":0},{"id":"2587446799","title":"BRIEF-Sichuan Biokin's Unit Receives $250 Mln Milestone Payment From BMS On Iza-Bren Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2587446799","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587446799?lang=en_us&edition=fundamental","pubTime":"2025-11-30 17:16","pubTimestamp":1764494203,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Biokin's Unit Receives $250 Mln Milestone Payment From BMS On Iza-Bren AgreementNov 30  - Sichuan Biokin Pharmaceutical Co Ltd 688506.SS:SAYS UNIT HAS RECEIVED $250 MILLION MILESTONE PAYMENT FROM BRISTOL-MYERS SQUIBB  RECENTLY IN ACCORDANCE TO IZA-BREN GLOBAL STRATEGIC AGREEMENTSAYS CO REMAINS ELIGIBLE FOR UP TO $250 MILLION NEAR-TERM PAYMENTS, UP TO $7.1 BILLION ADDITIONAL PAYMENTS UPON ACHIEVING SPECIFIC DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONESSource textFurther company coverage: 688506.SS  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251130:nL4N3X602O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0237698245.USD","IE00BSNM7G36.USD","LU0114720955.EUR","LU1032466523.USD","688506","LU1868837300.USD","LU1989771016.USD","LU0321505868.SGD","BK4559","LU0882574055.USD","LU0225771236.USD","LU1670710588.SGD","BK0239","LU1261432733.SGD","LU0456855351.SGD","LU1868836914.USD","IE00BFXG1179.USD","BMY","IE0009355771.USD","LU1291159041.SGD","BK4585","LU1868836591.USD","LU1093756325.SGD","LU1074936037.SGD","LU1670711040.USD","LU0225284248.USD","BK4532","BK4588","LU1093756168.USD","LU1323610961.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4534","LU1571399168.USD","LU1430594728.SGD","LU2125154778.USD","LU2242646821.SGD","LU0985481810.HKD","LU1868837136.USD","LU0868494617.USD","LU1670711123.USD","LU2133065610.SGD","LU0096364046.USD","LU0306807586.USD","LU2360032135.SGD","LU1585245621.USD","IE0002141913.USD","LU0267386448.USD"],"gpt_icon":0},{"id":"2587799127","title":"Sichuan Biokin Pharma  Says Unit Has Received $250 Mln Milestone Payment From Bristol-Myers Squibb Recently Regarding Iza-Bren Global Strategic Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2587799127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587799127?lang=en_us&edition=fundamental","pubTime":"2025-11-30 17:16","pubTimestamp":1764494202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251130:nL4N3X602O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4559","IE00B2B36J28.USD","IE0002141913.USD","BK4532","LU1868837300.USD","688506","LU1323610961.USD","LU0306806265.USD","LU0868494617.USD","BK4585","LU1868837136.USD","LU2125154778.USD","LU0985481810.HKD","IE00BJT1NW94.SGD","LU1571399168.USD","LU1261432733.SGD","LU2360032135.SGD","LU1430594728.SGD","LU1670711040.USD","LU1670711123.USD","LU0225284248.USD","IE00BFTCPJ56.SGD","LU1718418525.SGD","LU1093756168.USD","LU1868836914.USD","LU0306807586.USD","LU1868836591.USD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","LU2242646821.SGD","LU0237698245.USD","LU1989771016.USD","LU0225771236.USD","LU0321505868.SGD","BK4007","LU1093756325.SGD","BK4581","BMY","LU0096364046.USD","LU0456855351.SGD","LU1032466523.USD","LU1074936037.SGD","LU1670710588.SGD","LU2125154935.USD","LU0061475181.USD","IE0009355771.USD","LU1670710661.SGD","BK4534","LU0882574055.USD","BK4588"],"gpt_icon":0},{"id":"1169803746","title":"Sichuan Biokin Pharmaceutical (688506.SH) Subsidiary Receives $250 Million Milestone Payment from Bristol-Myers Squibb for Iza-Bren Project","url":"https://stock-news.laohu8.com/highlight/detail?id=1169803746","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169803746?lang=en_us&edition=fundamental","pubTime":"2025-11-30 17:00","pubTimestamp":1764493215,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) announced that its wholly-owned subsidiary, SystImmune, recently received a $250 million milestone payment from Bristol-Myers Squibb (BMY)....","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1261432733.SGD","LU0237698245.USD","LU1670711040.USD","LU1074936037.SGD","LU1032466523.USD","LU0225284248.USD","IE00BSNM7G36.USD","BK4534","LU0225771236.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","LU0114720955.EUR","BK4585","LU0267386448.USD","LU1868837300.USD","LU0321505439.SGD","LU0882574055.USD","LU1670711123.USD","LU0306807586.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0096364046.USD","LU0321505868.SGD","02615","LU1670710661.SGD","LU1989771016.USD","688506","BK4581","BK4007","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0306806265.USD","LU0868494617.USD","LU0061475181.USD","LU1670710588.SGD","LU0985481810.HKD","LU1291159041.SGD","LU2133065610.SGD","LU2242652126.USD","LU2360032135.SGD","91194","LU2125154778.USD","LU1571399168.USD","BK4532","LU1718418525.SGD","LU1868836757.USD","BMY","LU2242646821.SGD","LU1430594728.SGD","BK0239","BK4559","IE00BFXG1179.USD","LU1093756168.USD","LU1585245621.USD","LU1868836591.USD","LU1868837136.USD","LU2125154935.USD","IE00B2B36J28.USD","BK4588","LU1868836914.USD","LU1323610961.USD"],"gpt_icon":0},{"id":"2585437299","title":"Sichuan Biokin Pharmaceutical Gets Acceptance for Cancer Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2585437299","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585437299?lang=en_us&edition=fundamental","pubTime":"2025-11-24 11:52","pubTimestamp":1763956368,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  said its new drug application for innovative cancer treatment iza-bren has been accepted by China's medical products administrator.The drug is intended for locally advanced or metastatic nasopharyngeal carcinoma that failed prior treatments, according to a Monday filing with the Shanghai bourse.Shares of the pharmaceutical company were up 1% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02615","688506","BK0239"],"gpt_icon":0},{"id":"2584183711","title":"Sichuan Biokin Pharmaceutical Seeks Credit Support from Bank of China Sichuan Branch","url":"https://stock-news.laohu8.com/highlight/detail?id=2584183711","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584183711?lang=en_us&edition=fundamental","pubTime":"2025-11-20 15:33","pubTimestamp":1763624012,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  sought total credit support from the Bank of China  Sichuan branch for up to 8 billion yuan, according to a Thursday filing with the Shanghai bourse.Under their strategic cooperation agreement, the two parties will cooperate to improve foreign capital market operations, among others, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1224444064.USD","601988","BK0015","LU1497733631.SGD","BK0183","BK0278","LU0348805143.USD","LU0588546209.SGD","LU1048588211.SGD","LU2097828805.USD","03143","BK0028","LU0651947912.USD","LU2097828557.USD","02615","LU1051769294.HKD","LU1634259391.SGD","BK1521","SG9999001093.SGD","IE00BWDBJ730.SGD","LU1282651121.HKD","LU1522347837.USD","LU2097828714.EUR","LU0651946864.USD","LU1634259557.SGD","LU0293314216.USD","BK1560","SG9999006597.SGD","688506","IE00BQJZWZ67.USD","LU2097828474.EUR","LU1497733557.USD","BK1231","BK0012","LU2097828631.EUR","LU0307460666.USD","LU0072462343.USD","IE00B19Z5X02.USD","LU1051768304.USD","LU1515016050.SGD","LU1282651048.USD","BK0188","03988","LU1497734951.SGD","BK0239"],"gpt_icon":0},{"id":"2584910710","title":"Sichuan Biokin Pharma  Says Signs Agreement With Bank of China's Sichuan Branch to Receive No Less Than 8 Bln Yuan Worth of Credit","url":"https://stock-news.laohu8.com/highlight/detail?id=2584910710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584910710?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:00","pubTimestamp":1763550018,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV0TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2584100339","title":"BRIEF-Sichuan Biokin Pharma To Receive Credit Support From Bank Of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2584100339","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584100339?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:00","pubTimestamp":1763550018,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Biokin Pharma To Receive Credit Support From Bank Of ChinaNov 19  - Sichuan Biokin Pharmaceutical Co Ltd 688506.SS:SAYS SIGNS AGREEMENT WITH BANK OF CHINA'S SICHUAN BRANCH TO RECEIVE NO LESS THAN 8 BILLION YUAN  WORTH OF CREDITSource textFurther company coverage: 688506.SS  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV0TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688506","BK0239"],"gpt_icon":0},{"id":"1144162041","title":"Sichuan Biokin Pharmaceutical (688506.SH): Iza-bren Meets Dual Primary Endpoints in Phase III Trial for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1144162041","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144162041?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:28","pubTimestamp":1763425696,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) announced that its self-developed, first-in-class, novel-concept EGFR×HER3 bispecific antibody-drug conjugate (iza-bren), currently the only one in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","91194","02615","688506","BK4134","BK0239"],"gpt_icon":0},{"id":"1144480938","title":"Biokin's Hong Kong IPO Faces Sudden Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=1144480938","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144480938?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:00","pubTimestamp":1762959655,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin, 688506.SH), which had passed the Hong Kong Stock Exchange (HKEX) hearing in late October 2025, announced an unexpected delay in its H-share global...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEXmain","688506","02615","BK0239","91194"],"gpt_icon":0},{"id":"2582329724","title":"Sichuan Biokin Pharma  Says It Has Decided to Postpone Hong Kong Listing Due to Current Market Condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2582329724","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582329724?lang=en_us&edition=fundamental","pubTime":"2025-11-12 17:21","pubTimestamp":1762939293,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL4N3WO0L1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"1174274910","title":"Rare Move: BIOKIN (2615.HK) Delays IPO Just Before Closing—Why?","url":"https://stock-news.laohu8.com/highlight/detail?id=1174274910","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174274910?lang=en_us&edition=fundamental","pubTime":"2025-11-12 17:11","pubTimestamp":1762938661,"startTime":"0","endTime":"0","summary":"The red-hot Hong Kong IPO market witnessed an unusual case this year as Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) (new listing code: 2615.HK), already listed on the A-share market, abruptly...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["91194","02615","BK0239","688506"],"gpt_icon":0},{"id":"2582323763","title":"BRIEF-Sichuan Biokin Pharmaceutical Says Postponement Of Global Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2582323763","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582323763?lang=en_us&edition=fundamental","pubTime":"2025-11-12 16:23","pubTimestamp":1762935812,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Biokin Pharmaceutical Says Postponement Of Global OfferingNov 12 (Reuters) - Sichuan Biokin Pharmaceutical Co Ltd 688506.SS:POSTPONEMENT OF GLOBAL OFFERINGDECIDED THAT GLOBAL OFFERING WI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO003:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2582934387","title":"Sichuan Biokin Pharmaceutical Postpones Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2582934387","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582934387?lang=en_us&edition=fundamental","pubTime":"2025-11-12 11:46","pubTimestamp":1762919182,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  has decided to postpone its planned Hong Kong initial public offering, scheduled for Nov. 17, citing prevailing market conditions, according to a Wednesday bourse filing.The Chinese integrated pharmaceutical firm said it will not proceed with the offering as outlined in its November 7 prospectus, and the international and Hong Kong underwriting agreements will not take effect.Application monies for the Hong Kong public offering will be refunded in full without interest starting November 17, the filing said.Biokin added that the postponement does not affect its current operations while reassessing a new timetable.The firm launched its listing last week, aiming to raise up to HK$3.36 billion from the offering.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02615","BK0239","688506"],"gpt_icon":0},{"id":"2582934886","title":"Sichuan Biokin Pharmaceutical - Decided That Global Offering Will Be Postponed and Will Not Proceed Pursuant to Prospectus","url":"https://stock-news.laohu8.com/highlight/detail?id=2582934886","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582934886?lang=en_us&edition=fundamental","pubTime":"2025-11-12 11:17","pubTimestamp":1762917467,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO003:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2582488633","title":"Sichuan Biokin Pharmaceutical Co Ltd - Postponement of Global Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2582488633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582488633?lang=en_us&edition=fundamental","pubTime":"2025-11-12 11:17","pubTimestamp":1762917467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO003:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"1164256955","title":"BIOKIN (02615) Debuts on HKEX with Blockbuster ADC Drug Potential Exceeding $20 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1164256955","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164256955?lang=en_us&edition=fundamental","pubTime":"2025-11-11 09:04","pubTimestamp":1762823072,"startTime":"0","endTime":"0","summary":"Technology-driven innovation, surging demand, and policy support have been the three key drivers behind the sustained market enthusiasm for ADC drugs in recent years. For the Hong Kong stock market,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02615","BK0239","688506","91194"],"gpt_icon":0},{"id":"2581044266","title":"Sichuan Biokin Pharma Launches Up to HK$3.4 Billion Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2581044266","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581044266?lang=en_us&edition=fundamental","pubTime":"2025-11-07 07:18","pubTimestamp":1762471090,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  launched its initial public offering in Hong Kong on Friday, targeting to raise as much as HK$3.36 billion from the deal.The Chinese integrated pharmaceutical group is offering as many as 8,634,300 shares, expected to be priced in a range of HK$347.50 to HK$389.00, according to an early morning filing with the Hong Kong bourse on Friday.The offer price is expected to be determined on Nov. 13, with the allocation results to be disclosed a day after, ahead of the company's trading debut on the bourse on Nov. 17.Sichuan Biokin Pharma attracted Bristol-Myers Squibb, OrbiMed Asia Partners III's AOP III, Fullgoal Fund, GL Capital and Athos Capital as cornerstone investors, which agreed to subscribe to US$32 million of the shares on offer.Net proceeds, estimated at HK$3.02 billion, will be used to fund the R&D of its biologic drug candidates outside of China, to establish global supply chain, and for working capital and other general corporate purposes.Goldman S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"1153696444","title":"Sichuan Biokin Pharmaceutical (02615) Opens IPO Subscription from Nov 7 to Nov 12, Expected Listing on Nov 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1153696444","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153696444?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:56","pubTimestamp":1762469789,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical (02615) has announced its initial public offering (IPO) subscription period from November 7 to November 12, 2025. The company plans to issue 8.6343 million shares...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02615","688506","BK0239"],"gpt_icon":0},{"id":"2581715630","title":"Biokin Pharmaceutical's T-Bren for Injection Placed in China's List of Breakthrough Therapy Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2581715630","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581715630?lang=en_us&edition=fundamental","pubTime":"2025-11-05 11:22","pubTimestamp":1762312955,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical's  T-Bren for injection  is included in the Chinese drug administration's list of breakthrough therapy drugs, according to a Shanghai bourse filing on Wednesday.The drug is used for the treatment of patients with gastroesophageal junction adenocarcinoma who have failed prior first-line anti-HER2 therapy and standard first-line chemotherapy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688506","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","stockEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0025},{"period":"3month","weight":0.029},{"period":"6month","weight":0.1058},{"period":"1year","weight":0.711},{"period":"ytd","weight":0.8773}],"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","perCapita":"17208股","boardName":"医药制造业","registeredCapital":"41287万元","compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"survey":"　　四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","serverTime":1765709682561,"listedPrice":24.7,"stockholders":"5979人(较上一季度增加25.08%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sichuan Biokin Pharmaceutical Co.,Ltd.(688506),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sichuan Biokin Pharmaceutical Co.,Ltd.(688506) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sichuan Biokin Pharmaceutical Co.,Ltd.,688506,Sichuan Biokin Pharmaceutical Co.,Ltd.股票,Sichuan Biokin Pharmaceutical Co.,Ltd.股票老虎,Sichuan Biokin Pharmaceutical Co.,Ltd.股票老虎国际,Sichuan Biokin Pharmaceutical Co.,Ltd.行情,Sichuan Biokin Pharmaceutical Co.,Ltd.股票行情,Sichuan Biokin Pharmaceutical Co.,Ltd.股价,Sichuan Biokin Pharmaceutical Co.,Ltd.股市,Sichuan Biokin Pharmaceutical Co.,Ltd.股票价格,Sichuan Biokin Pharmaceutical Co.,Ltd.股票交易,Sichuan Biokin Pharmaceutical Co.,Ltd.股票购买,Sichuan Biokin Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sichuan Biokin Pharmaceutical Co.,Ltd.(688506),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sichuan Biokin Pharmaceutical Co.,Ltd.(688506) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction